Septerna (SEPN) Non-Current Assets (2023 - 2026)
Septerna's quarterly Non-Current Assets came in at $201.6 million in Q1 2026, up 120.24% year-on-year from $91.6 million in Q1 2025, and up 8.86% quarter-over-quarter from $185.2 million in Q4 2025.
Septerna has reported Non-Current Assets for 4 years, with the latest figure at $201.6 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 120.24% year-over-year to $201.6 million; the trailing twelve-month figure through Mar 2026 stood at $582.9 million (up 132.85% YoY), and the FY2025 full-year result was $185.2 million, up 85.72% from the prior year.
- Non-Current Assets for Q1 2026 stood at $201.6 million, up from $185.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $201.6 million in Q1 2026, with the low at $18.2 million in Q4 2023.
- Average Non-Current Assets over 4 years is $104.2 million, with a median of $95.6 million recorded in 2024.
- Year-over-year, Non-Current Assets jumped 448.3% in 2024 and surged 85.72% in 2025.
- Tracing SEPN's Non-Current Assets over 4 years: stood at $18.2 million in 2023, then jumped by 448.3% to $99.7 million in 2024, then surged by 85.72% to $185.2 million in 2025, then climbed by 8.86% to $201.6 million in 2026.
- The last three Non-Current Assets figures came in at $201.6 million (Q1 2026), $185.2 million (Q4 2025), and $115.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Septerna | 1.34 Bn | 1.34 Bn | - | 201.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201.63 Mn |
| Dec 31, 2025 | 185.22 Mn |
| Sep 30, 2025 | 114.97 Mn |
| Jun 30, 2025 | 81.09 Mn |
| Mar 31, 2025 | 91.55 Mn |
| Dec 31, 2024 | 99.73 Mn |
| Sep 30, 2024 | 40.87 Mn |
| Dec 31, 2023 | 18.19 Mn |